Search
Verastem Inc
VSTMAdd to Watchlist
4.120USD
-0.050-1.20%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
361.91MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Verastem Inc is 8.67, ranking 77 out of 389 in the Biotechnology & Medical Research industry. The average price target is 15.50, with a high of 20.00 and a low of 14.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
16.000
Target Price
+283.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Verastem Inc
VSTM
9
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Verastem Inc's expected revenue for the next quarter?
Verastem Inc's expected revenue is 23.35M.
What is Verastem Inc's price target?
Analysts forecast that Verastem Inc's price target is USD 15.50, with the highest forecast at USD 20.00 and the lowest forecast at USD 14.00.
How have Verastem IncVSTM's recent earnings per share performed?
The market expectation was USD -0.37, while Verastem IncVSTM's earnings per share (EPS) for the previous quarter was USD -0.39. EPS for the next quarter is expected at USD -0.45.
What is the analyst rating for Verastem Inc?
Based on the ratings of Verastem Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
